Who
David C. Hastings
Director
Company insider
Files Form 4 as: Director, Scynexis; Chief Financial Officer, Trevi Therapeutics; Chief Financial Officer, Arbutus Biopharma; Director, Entasis Therapeutics Holdings; Officer, Unilife; Chief Financial Officer, Incyte.
In numbers
- Trades disclosed
- 138
- Buys
- 5
- Sells
- 10
- Bought
- $94K
- Sold
- $36.3M
- Companies
- 6
- Companies where not an officer
- 2
- First trade
- 13 Jan 2006
- Last trade
- 26 Jun 2026
- Last filed
- 30 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Jun 2026filed 30 Jun 2026 | SCYX ScynexisBiotechnology | SEC FORM 4 Code A | —2,875 at $0.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,875 at $0.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,875 at $0.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | SCYX ScynexisBiotechnology | SEC FORM 4 Code A | —2,875 at $0.00 | filing |
| 8 Jan 2026filed 12 Jan 2026 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —375,000 at $0.00 | filing |
| 8 Jan 2026filed 12 Jan 2026 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —375,000 at $0.00 | filing |
| 26 Jun 2025filed 30 Jun 2025 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,000 at $0.00 | filing |
| 26 Jun 2025filed 30 Jun 2025 | SCYX ScynexisBiotechnology | SEC FORM 4 Code A | —23,000 at $0.00 | filing |
| 14 Feb 2025filed 19 Feb 2025 | ABUS Arbutus Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —365,800 at $0.00 | filing |
| 14 Feb 2025filed 19 Feb 2025 | ABUS Arbutus BiopharmaBiotechnology | SEC FORM 4 Code A | —90,100 at $0.00 | filing |
| 4 Feb 2025filed 5 Feb 2025 | ABUS Arbutus BiopharmaBiotechnology | SEC FORM 4 Sold | $73K22,183 at $3.28 | filing |
| 20 Jun 2024filed 21 Jun 2024 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,000 at $0.00 | filing |
| 20 Jun 2024filed 21 Jun 2024 | SCYX ScynexisBiotechnology | SEC FORM 4 Code A | —23,000 at $0.00 | filing |
| 2 Feb 2024filed 5 Feb 2024 | ABUS Arbutus BiopharmaBiotechnology | SEC FORM 4 Sold | $22K9,593 at $2.31 | filing |
| 1 Feb 2024filed 5 Feb 2024 | ABUS Arbutus Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —450,000 at $0.00 | filing |
| 1 Feb 2024filed 5 Feb 2024 | ABUS Arbutus BiopharmaBiotechnology | SEC FORM 4 Code A | —112,500 at $0.00 | filing |
| 15 Jun 2023filed 23 Jun 2023 | SCYX ScynexisBiotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 15 Jun 2023filed 20 Jun 2023 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 1 Feb 2023filed 3 Feb 2023 | ABUS Arbutus Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —316,000 at $0.00 | filing |
| 1 Feb 2023filed 3 Feb 2023 | ABUS Arbutus BiopharmaBiotechnology | SEC FORM 4 Code A | —79,000 at $0.00 | filing |
News
Comparing Madrigal Pharmaceuticals (NASDAQ:MDGL) and Incyte (NASDAQ:INCY)INCY · themarketsdaily.com · 20 Oct 2026Contrasting Arbutus Biopharma (NASDAQ:ABUS) and Evaxion A/S (NASDAQ:EVAX)ABUS · tickerreport.com · 18 Oct 2026Reviewing Arbutus Biopharma (NASDAQ:ABUS) & Prelude Therapeutics (NASDAQ:PRLD)ABUS · tickerreport.com · 17 Oct 2026Arbutus Biopharma (NASDAQ:ABUS) vs. Immunome (NASDAQ:IMNM) Financial ComparisonABUS · themarketsdaily.com · 12 Oct 2026
0 headlines in the last 90 days name David C. Hastings; 4 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.